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Abstract
We previously reported that the biological activity of analogues of desmosdumotin B (1) was
dramatically changed depending on the B-ring system. A naphthalene B-ring analogue 3 exerted
potent in vitro activity against a diverse panel of human tumor cell lines with GI50 values of 0.8–
2.1 μM. In contrast, 1-analogues with a phenyl B-ring showed unique selective activity against P-
glycoprotein (P-gp) overexpressing multidrug resistance cell line. We have now prepared and
evaluated 1-analogues with bicyclic or tricyclic aromatic B-ring systems as in vitro inhibitors of
human cancer cell line proliferation. Among all synthesized derivatives, 21 with a
benzo[b]thiophenyl B-ring was highly active, with GI50 values of 0.06–0.16 μM, and this activity
was not influenced by overexpression of P-gp. Furthermore, 21 inhibited tubulin assembly in vitro
with an IC 50 value of 2.0 μM and colchicine binding by 78% as well as cellular microtubule
polymerization and spindle formation.
Introduction
We previously reported that desmosdumotin B (1, Figure 1) exerted selective inhibition of a
P-glycoprotein (P-gp) overexpressing multidrug resistant (MDR) tumor cell line with
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significantly lower activity against non-MDR tumor cells.1 The observed selectivity index
[collateral sensitivity (CS),2 activity ratio of MDR line versus non-MDR line] was greater
than 20. This selective in vitro antitumor activity was further enhanced by replacing the
three methyl groups at C-6 and C-8 with ethyl groups (2, Figure 1) and also adding an alkyl
group at the C-4′ position. During this study, we also found that analogues in which the
phenyl B-ring was replaced with a naphthyl moiety (3, Figure 1) had dramatically different
activity profiles, displaying strong cytotoxicity against multiple cancer cells, regardless of
MDR expression, with GI 50 values of 0.8–2.1 μM. Thus, placing a larger, more electron-
rich aromatic B-ring at C-2 resulted in broader antiproliferative activity and loss of specific
activity against the MDR cell line. These compounds also induced rapid cell rounding
without immediate detachment, leading us to hypothesize anti-tubulin activity as a
mechanism of action, which was tested and confirmed using biochemical assays. Compound
3, therefore, represents a new scaffold for targeting tubulin assembly.
Design and synthesis of compounds targeting the microtubule constitutes an attractive
strategy for the discovery of new antitumor agents.3 The microtubule network is an essential
component of the cytoskeleton, and its timely depolymerization and repolymerization is
critical for the cell to construct a functional mitotic spindle. Typically, cells arrested in
apparent mitosis eventually undergo apoptosis. Antimitotic agents targeting tubulin are
generally classified into two groups, compounds that either stimulate or inhibit microtubule
assembly, depending on their effects on the tubulin-microtubule equilibrium. Taxoids and
epothilones are well-known enhancers of microtubule polymerization. Colchicine and the
vinca alkaloids are the best known inhibitors of microtubule assembly. All of these agents
bind to β–tubulin to exert their antimitotic activity. The best characterized drug binding
domains are known as the colchicine site, the vinca domain, and the taxoid site.
The vinca alkaloids and the taxoids are among the most useful drugs for cancer therapy, and
numerous compounds targeting drug binding sites on tubulin have been developed.
Unfortunately, most antitubulin agents that have entered clinical trials have failed due to
adverse effects, such as limited therapeutic effects at maximally tolerated doses, perhaps
because of drug resistance, high toxicity, or poor physicochemical properties involved in the
absorption, distribution, metabolism, and excretion profile. Interestingly, thus far, no
colchicine site drug has proved useful in cancer treatment. Despite its lack of utility in
cancer therapy, colchicine is used for the treatment of gout, familial Mediterranean fever,
secondary amyloidosis, and scleroderma. Moreover, colchicine has long been an important
tool for the study of microtubule structure/function4 and a key molecular model for
structure-activity relationship studies. Previous research revealed that a two-ring aromatic
system with the rings either directly bonded or separated by a one to three atom bridge is a
common structural feature for binding to the colchicine site.5 Combretastatin A-4 (CA-4) is
an attractive natural product that targets tubulin polymerization via the colchicine site. CA-4
exerts strong cytotoxicity against multiple human tumor cell lines.6 The discovery of CA-4
and its simple molecular structure stimulated research to identify new chemotypes that
interact with the colchicine site.
Our interesting discovery of 2-naphthyldesmosdumotin B (3) as an antitubulin agent
prompted us to prepare additional 3-analogues with bicyclic and tricyclic aromatic
substituents at C-2. In the work presented here, we describe the syntheses and bioactivities
of this compound series.
Chemistry
Thirty-four newly synthesized analogues, 4–37, are depicted in Figure 1. They were
synthesized from 38 (R = Et for 6–34, R = Me for 4 and 35–37, and R = Pr for 5) 1 through
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the related chalcones (39) as shown in Scheme 1.1,7 The chalcones (39) were prepared by
the Claisen-Schmidt condensation of 38 with various commercially available aromatic
aldehydes (ArCHO), except for 55 and 56. In most cases, the condensation was carried out
in the presence of 50% aq. KOH in EtOH. However, under these conditions, the reaction
with 3-quinoline aldehyde resulted in extremely low yields of product. Finally, the reactions
were run with good yields in the presence of piperidine or Ba(OH)2·H2O. The iodine-
catalyzed cyclization of 39, followed by demethylation, provided 3–37. The treatment of 3
(R = Et, Ar = naphthyl) with excess Lawesson’s reagent8 resulted in replacement of oxygen
with sulfur to yield both the mono-thioketone 41 and the di-thioketone 42. The structure of
41 was determined from the 1H-NMR and MS spectra, which indicated the insertion of a
sulfur atom. Compared to the 1H-NMR of the related compound 3, the spectra of 41 showed
a 0.79 ppm high field shift of a proton at the C-3 position and no shift for the ethyl protons
at the C-6 and C-8 positions. There was, however, a high field shift for the ethyl protons of
di-thioketone 42 (Table 1). Bromination of 40a (R = Et, Ar = naphthyl) with nBu4NBr in the
presence of PhI(OAc)29 afforded 3-bromo derivative 43, which was converted to 44 by
demethylation with BBr3. Meanwhile, flavanone analogue 48 was prepared by the treatment
of 39 with HI in HOAc.
Aldehydes 55 and 56 were prepared as shown in Scheme 2. We originally expected that 5-
methoxy- and 5-methyl-benzothiophene, 5310 and 54,11 could be obtained from the related
3-carboxyaldehydes through formylation.12 While Rieche formylation of 5-
methybenzothiophene (54) using SnCl4 provided the desired 3-carboxaldehyde 56 in good
yield, the same treatment of 5-methoxybenzothiophene (53) unexpectively produced 4-
formyl product 55. The structure of 55 was identified by 1H-NMR, which showed two
doublet signals with a coupling constant of 5.6 Hz at 8.39 and 7.65 ppm for the C-3 and C-2
protons, respectively. Furthermore, nOe crosspeaks were observed between the aldehyde
and methoxy protons, the aldehyde and C-3 protons, as well as the methoxy and C-6
protons. The interesting difference in reactivity between the 5-methyl and 5-methoxy groups
might be caused by a chelation effect of the Lewis acid with the oxygen atom of the
methoxy group.
Newly synthesized analogues could be classified into the following five groups according to
the C-2 substituent: I) naphthalene group (3–12 and 35), II) heterobicyclic aromatic group
(13–28, 36 and 37), III) tricyclic aromatic group (29–33), IV) biphenyl group (34) and V)
naphthalane group with A- and/or C-ring modifications (40a–44 and 48).
Results and Discussion
All new analogues were evaluated against seven human tumor cell lines, specifically,
HCT-8 (colon adenocarcinoma), PC-3 (prostate cancer), A549 (lung carcinoma), MCF-7
(breast cancer) or DU145 (prostate cancer), HepG2 (hepatocellular carcinoma), and KB
(epidermoid carcinoma of the nasopharynx), and KB-VIN, which is an MDR (P-gp-
overexpressing) KB subline selected using increasing concentrations of vincristine. The
selected active compounds 3, 6, 8, 11, 15, 21, 22, 26, and 35–37 were also tested for
inhibitory effects on tubulin assembly and inhibition of binding of [3H]colchicine to tubulin,
together with 2 for comparison. Table 2 lists the antiproliferative data for 1–48 and
vincristine, the positive control. The tubulin study data are presented in Table 3.
Mono-phenyl analogues 1 and 2 were clearly “non-active” against all non-MDR tumor cells
(2 was also inactive in the tubulin assembly assay), while they were “active” against the P-
gp overexpressing MDR tumor cell line KB-VIN. In comparison, most analogues with a
bicyclic substituent at C-2 (Groups-I and -II) showed in vitro activity against all tested cell
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lines, with GI50 values ranging from 0.1 to 20 μM, while three of the five analogues (30–32)
with a tricyclic substituent at C-2 (Group-III), were inactive.
With respect to the alkyl groups at C-6 and C-8, the 6,8,8-tri-Me (4) and tri-Et (3) analogues
showed similar growth inhibitory activity against the tested tumor cell lines, while the
tripropyl analogue 5 was much less active.
Group-II compound 21, with a tri-Et A-ring and a benzo[b]thiophene B-ring at C-2, had
dramatically increased antiproliferative activity, exhibiting GI50 values of 0.06–0.16 μM
against the human tumor cell lines. Although the activity of 37, with a tri-Me A-ring and a
benzo[b]thiophene B-ring at C-2, was less than that of 21, it still showed potent activity with
GI50 values of 0.09–1.08 μM. In comparison, the related analogue 17, with the chromene
skeleton attached at the 2′-position of the benzo[b]thiophene system rather than at the 3′-
position, showed considerally lower activity against all cell lines (GI50 = 3.8–19.0 μM), with
significant activity only against PC-3. The replacement of sulfur (21) with oxygen (19) or N-
methyl (20) led to reduced activity. Other relatively active analogues, with mostly
submicromolar GI 50 values, were tri-Et compounds 3, 6, 8, 11 and 15, as well as the related
tri-Me analogues 4 and 35–37. All of these compounds had a naphthyl B-ring at C-2, except
for 15 and 36, which had a 2,3-dihydrobenzo[1,4]dioxine group at C-2. Quinoline 13,
benzofurans 16 and 19, as well as indole 20, each bearing a bicyclic heteroaromatic B-ring
system, displayed only moderate activity against all tested cell lines. Analogue 14, with a
benzo[1,3]dioxolyl B-ring system, also moderately inhibited tumor cell growth, although it
was about 10 times less active than 21. These data demonstrated that, although a 10π-
electron B-ring system was optimal, it was not essential for activity. Among the Group-III
compounds, those with the three rings arranged linearly were inactive, while compound 29
(C-2 dihydroacenaphthyl) showed significant antiproliferative activity. Compounds 33 (C-2
phenanthryl) and 34 (C-2 biphenyl) showed only moderate potency.
When the ketone oxygen at C-7 was replaced with a methoxy group (3 vs 40a), there was a
substantial loss of activity (GI50 values of 0.8–2.1 μM for 3 and 9.7–20.9 μM for 40a). The
latter compounds would lose the possibility of a hydrogen bond between the C-4 ketone
carbonyl and the C-5 hydroxy group, which might account for the difference in potency.
Activity also decreased when a bromide group was inserted at the C-3 position (3 vs 44),
although the bromine atom had no effect when a C-7 methoxy group was present (cf. 40a
and 43). Reduced activity also occurred when both oxygens in the C-4 and C-7 ketones were
changed to sulfur (3 vs 42). However, mono-thioketone 41 retained relatively good activity,
as compared with 3, against A549 and KB cells, with GI50 values of 1.86 and 1.41 μM,
respectively. The saturation of the double bond between C2 and C3 also decreased activity
(3 vs 48). Finally, it should be pointed out that MDR KB-VIN cells were as sensitive as the
parental KB cells to all active compounds.
Because compound 21, containing a benzo[b]thiophene system, showed potent
antiproliferative activity, we investigated additional related derivatives 22–28. While none
of these compounds showed greater activity than 21, some interesting facts were revealed. 1)
The 2′-Me derivative (22) retained activity against all tested cell lines, except PC-3. 2) 5′-
Me (23) and 5′-Br (24) analogues lost activity. 3) Activity varied with the position of
attachment of the benzo[b]thiophene system to the chromene skeleton. The rank order of
overall activity was 3′ (21) > 7′ (27) > 2′ (17) >5′ (28). 4) Compound 28 displayed selective
activity against the DU145 and KB cell lines. 5) Compound 26 (5′-OH) exhibited potent
cytotoxicity against all tested cell lines, while 25 (5′-OMe) lost activity against most cell
lines. 6) Compounds 24 and 27 possessed “collateral sensitivity” (CS),2 exhibiting over two-
fold greater cytotoxicity against the MDR line (KB-VIN) than against the parental line
(KB). Figure 2 shows the reversal effects of co-treatment of 24 or 27 together with a
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nontoxic concentration of verapamil (VERAP), a known P-gp modulator. Co-treatment of
24 and 27 with VERAP partially reversed the cytotoxic activity, showing that the MDR-
selectivity was dependent in part on P-gp function and consistent with the effect on P-gp
activity measured using the co-incubation treatment protocol. This result is consistent with
data obtained with analogues of 1 containing a phenyl B-ring.13
We observed that cells treated with cytotoxic concentrations of these agents displayed a
characteristic rounded shape, that was morphologically similar to the cells treated with
colchicine, when examined microscopically. We explored microtubules and spindles in
A549 cells treated with 21. The A549 cells were treated with 21, colchicine, pacritaxel,
doxorubicine, or DMSO for 24 hr followed by the immunofluorescence staining of tubulin
using monoclonal antibody to α-tubulin. As we expected, microtubule polymerization and
spindle formation were significantly inpaired by treatment with 21, that were similar to the
effects of colchicine and clearly different from pacritaxel or doxorubicine (Figure 3). The
antimicrotubule activity of 21was seen within 24 hr at the concentration of 0.1 nM which
was 1000 fold less than colchicine (100 nM).
We therefore evaluated selected active compounds for antitubulin activities, and the results
are shown in Table 3. All cytotoxic compounds (GI50 values of less than 1 μg/mL) also
exhibited potent inhibition of tubulin assembly. Analogue 21, which showed the most potent
cytotoxicity, strongly inhibited tubulin assembly with an IC50 value of 2.0 μM. It was also
the most active of these compounds as an inhibitor of colchicine binding to tubulin,
inhibiting the binding reaction by 78%. Its trimethyl analogues 35–37 and cytotoxic
analogues 3, 6, 8, 21, 22, and 26 also inhibited tubulin assembly, with IC50 values of 2.3–3.7
μM, althoguh these compounds were less active than 21 as inhibitors of colchicine binding.
Compounds 11 and 15 were even less active, and 2 had no significant interaction with
tubulin at the highest concentration evaluated (40 μM). Thus, we made conclusion that 21 is
a potent tubulin polymerization inhibitor.
In 2005, Nguyen et al studied fifteen colchicine site inhibitiors (CSIs) and proposed seven
pharmacophoric points based on consistent structural features and recurring ligand
interactions 14 The seven points were three hydrogen bond acceptors (A1, A2 and A3), one
hydrogen bond donor (D1), two hydrophobic centers (H1 and H2) and one planar group
(R1). The H2 and R1 points represented the rigid portion of the molecular scaffold, while
the other five points were important for binding specificity. Nguyen et al14 also mentioned
that A2, H1, H2 and R1 emerged as essential features for inhibitory activity at the
colchicines site. Most of the fifteen CSIs contained five to six of the seven pharmacophoric
points. For example, Figure 4a shows that the well-known tubulin polymerization inhibitors,
colchicine and CA-4, map to five pharmacophoric points, A1, A2, D1, H2, and R1. Figure
4b overlays the structures of colchicine and CA-4 onto a 3D picture of the five
pharmacophores. We used Molecular Operating Environment (MOE) software to search for
the best-fit 3D conformations of three of our active compounds, 3, 21 and 26, with the five
pharmacophore features. The superpositions are shown in Figure 5. The ring systems of 3,
21, and 26 matched well with the planar center (R1) and hydrophobic center (H2), which are
critical portions for the molecular scaffold. In addition, the hydrogen acceptor (A1) and
hydrogen bond donor (D1) pharmacophores overlapped with the oxygen at the 4-position
and hydroxyl group at the 5-position, respectively, of 3, 21, and 26. Compound 21 showed a
better fit to the pharmacophore points R1 and H2 than compounds 3 and 26, which could
explain the greater inhibitory activity of 21 against the colchicine binding site. Another
possible reason of its great potency is that the sulfur atom in 21 might interact positively
with the binding site. Further structural modifications to enhance expression of one or more
of the other three pharmacophore features, A2, A3, and H1, could increase the potency of
these tubulin-destabilizing agents targeting the colchicine site.
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In summary, we discovered that analogues of 1 with bicyclic aryl substituents at C-2
possessed promising antitumor activity, with significant antiproliferative effects against
HCT-8, PC-3, A549, MCF-7, HepG2, KB, and KB-VIN tumor cells. Benzo[b]thiophene
analogue 21 displayed the most potent inhibitory effects on tumor cell growth, with GI50
values of 0.06–0.16 μM. The activity of the compounds, including 21, was not influenced by
overexpression of P-gp (GI50 = 0.07 μM against KB-VIN vs 0.08 μM for the parental KB
line). Furthermore, cytotoxicic analogues 3, 6, 8, 11, 15, 21, 22, 26, and 35–37, which all
possess a bicyclic B-ring at C-2, displayed significant antitubulin activities with 30–80%
inhibition of binding to the colchicine site. Compounds 3, 21, and 26 overlapped with four
out of seven pharmacophoric points that were derived from the binding models of fifteen
selected CSIs. Thus, they are a new class of CSIs, and further modifications would be useful
to develop more potent antitubulin agents. However, analogues of 1 with a phenyl B-ring,
including the natural product 1 itself, showed selective cytotoxicity against KB-VIN cells
relative to KB cells. Thus, the results presented here indicate that the B-ring structure is
critically important in the interaction of this compound class with P-gp. This distinction may
well prove valuable in designing more effective chemotherapeutic agents.
Experimental
All chemicals and solvents were used as purchased. All melting points were measured on a
Fisher-Johns melting point apparatus without correction. 1H and 13C NMR spectra were
recorded on a Varian Gemini 2000 (300 MHz) or a Varian Inova (400 MHz) NMR
spectrometer with TMS as the internal standard. All chemical shifts are reported in ppm.
NMR spectra were referenced to the residual solvent peak, chemical shifts d in ppm,
apparent scalar coupling constants J in Hz. Mass spectroscopic data were obtained on a
Shimazu LC-MS2010 instrument. Analytical thin-layer chromatography (TLC) was carried
out on Merck precoated aluminum silica gel sheets (Kieselgel 60 F-254). Biotage Flash or
Isco Companion systems were used for flash chromatography. All target compounds were
characterized and determined as at least >95% pure by 1H-NMR, MS, and elemental
analyses or analytical HPLC.
General synthetic procedures for 31
A solution of 30 in EtOH–50% aq. KOH (1:1, v/v) and an appropriate aromatic aldehyde
(excess) was stirred at room temperature. After the reaction was complete by TLC analysis,
the mixture was poured into ice-cold 1 N HCl, and then extracted with CH2Cl2. The extract
was washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was
chromatographed on silica gel with CH2Cl2–hexane as eluent to afford the target compound,
which was crystallized from CH2Cl2–hexane.
General synthetic procedures for 3–37
Compound 39 was dissolved separately in 1% H 2SO4 in DMSO, then I2 (0.1 eq. mol) was
added and the reaction mixture heated at 90 °C for 1 h. The reaction mixture was treated in
the same manner as described above to afford compound 40, which was dissolved in
anhydrous CH2Cl2. BBr3 (3 eq. mol, 1.0 M solution in CH2Cl2) was added to the solution at
0 ºC, which was warmed to rt spontaneously and stirred overnight. After addition of water,
the reaction mixture was extracted three times with CH2Cl2. The extracts were combined,
washed with brine, dried over Na2SO4 and concentrated in vacuo. The residues were
chromatographed on silica gel eluting with EtOAc-hexane (1:4) to obtain analogs 5–37.
2-(Naphthalen-1′-yl)-6,8,8-tripropyldesmosdumotin B (5)
1H NMR (300 MHz, CDCl3): δ̣ 13.07 (s, 1H, chelated-OH), 8.09 (d, 1H, J = 7.9 Hz, 5′-H),
8.01–7.97 (m, 1H, 4′ or 8′-H), 7.92–7.86 (m, 1H, 4′ or 8′-H), 7.70–7.58 (m, 4H, J = 7.3 Hz,
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2′, 3′ 6′ and 7′-H), 6.80 (s, 1H, 3-H), 2.43 (t, 2H, J = 7.5 Hz, 6-CH2CH2CH3), 2.12 (dt, 2H, J
= 12.5 and 4.3 Hz, 8-CH2CH2CH3), 1.83 (dt, 2H, J = 12.5 and 4.3 Hz, 8-CH2CH2CH3), 1.49
(q, 2H, J = 7.7 Hz, 6-CH2CH2CH3), 1.24–1.11 (m, 2H, 8- CH2CH2CH3), 1.10–0.50 (m, 2H,
8- CH2CH2CH3), 0.96 (t, 3H, J = 7.7 Hz, 6-CH2CH2CH3), 0.82 (t, 6H, J = 7.5 Hz, 8-
CH2CH3×2). MS (ESI+) m/z: 431 (M++1). Anal. (C28H30O4) C, H, O.
2-(4′-Methylnaphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (6)
1H NMR (300 MHz, CDCl3):δ 13.11 (s, 1H, chelated-OH), 8.17–8.12 (m, 1H, 5′-H), 7.97–
7.92 (m, 1H, 8′-H), 7.70–7.56 (m, 2H, 6′- and 7′-H), 7.58 (d, 1H, J = 7.3 Hz, 2′-H), 7.46 (d,
1H, J = 7.3 Hz, 3′-H), 6.79 (s, 1H, 3-H), 2.80 (s, 3H, 4′-CH3), 2.48 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.26–2.12 (m, 2H, 8-CH2CH3), 1.96–1.84 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J =
7.3 Hz, 6-CH2CH3), 0.72 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). Anal. (C26H26O4·1/4H2O) C,
H, O.
2-(2′-Methylnaphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (7)
1H NMR (300 MHz, CDCl 3): δ̣ 13.05 (s, 1H, chelated-O 3 H), 7.96 (d, 1H, J = 8.7 Hz, 4′-
H), 7.94–7.88 (m, 1H, 5′-H), 7.58–7.48 (m, 3H, 6′, 7′and 8′-H), 7.46 (d, 1H, J = 8.7 Hz, 3′-
H), 6.64 (s, 1H, 3-H), 2.49 (q, 2H, J = 7.5 Hz, 6-CH2CH3), 2.46 (s, 3H, 2′-CH3), 2.20–2.06
(m, 2H, 8-CH2CH3), 1.88–1.74 (m, 2H, 8-CH2CH3), 1.07 (t, 3H, J = 7.3 Hz, 6-CH2CH3),
0.69 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 403 (M++1). Anal. (C26H26O4·1/4H2
O) C, H, O.
2-(4′-Methoxynaphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (8)
1H NMR (300 MHz, CDCl3):δ 13.19 (s, 1H, chelated-OH), 8.40 (dd, 1H, J = 7.3 and 2.2 Hz,
5′-H), 7.94 (dd, 1H, J = 7.3 and 2.2 Hz, 8′-H), 7.65 (d, 1H, J = 8.0 Hz, 2′-H), 7.65–7.56 (m,
2H, 6′ and 7′-H), 6.93 (d, 1H, J = 8.0 Hz, 3′-H), 6.78 (s, 1H, 3-H), 4.10 (s, 3H, -OCH3), 2.48
(q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.24–2.12 (m, 2H, 8-CH2CH3), 1.99–1.84 (m, 2H, 8-
CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.72 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS
(ESI+) m/z: 419 (M++1). Anal. (C26H26O5) C, H, O.
2-(4′,7′-Dimethoxynaphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (9)
1H NMR (300 MHz, CDCl3): δ̣ 13.22 (s, 1H, chelated-OH), 8.31 (d, 1H, J = 10.0 Hz, 5′-H),
7.59 (d, 1H, J = 8.2 Hz, 2′-H), 7.24 (d, 1H, J = 10.0 Hz, 6′-H), 7.23 (s, 1H, 2′-H), 6.80 (d,
1H, J = 8.2 Hz, 3′-H), 6.77 (s, 1H, 3- H), 4.07 (s, 3H, -OCH3), 3.89 (s, 3H, -OCH3), 2.48 (q,
2H, J = 7.4 Hz, 6-CH2CH3), 2.27–2.13 (m, 2H, 8-CH2CH3), 2.01–1.87 (m, 2H, 8-CH2CH3),
1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z:
449 (M++1). Anal. (C27H28O6·1/4H2O) C, H, O.
2-(2′,3′-Dimethoxynaphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (10)
1H NMR (300 MHz, CDCl3): δ̣ 13.09 (s, 1H, chelated-OH), 7.81 (d, 1H, J = 8.2 Hz, 5′-H),
7.54–7.38 (m, 3H, 6′,7′ and 8′-H), 7.49 (s, 1H, 4′-H), 6.67 (s, 1H, 3-H), 4.05 (s, 3H, -OCH3),
3.89 (s, 3H, -OCH3), 2.49 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.20–2.06 (m, 2H, 8-CH2CH3),
1.92–1.78 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.69 (t, 6H, J = 7.4 Hz,
8-CH2CH3×2). MS (ESI+) m/z: 449 (M++1). Anal. (C27H28O6·H2O) C, H, O.
2-(Naphthalen-2′-yl)-6,8,8-triethyldesmosdumotin B (11)
1H NMR (300 MHz, CDCl3):δ̣ 13.10 (s, 1H, chelated-OH), 8.33 (d, 1H, J = 1.8 Hz, 1′-H),
8.04–7.96 (m, 2H, 5′- and 8′-H), 7.96–7.90 (m, 1H, 4′-H), 7.80 (dd, 1H, J = 1.8 and 8.5 Hz,
3′-H), 7.69–7.60 (m, 2H, 6′ and 7′-H), 7.04 (s, 1H, 3-H), 2.48 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.38–2.24 (m, 2H, 8-CH2CH3), 2.15–2.01 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J =
Nakagawa-Goto et al. Page 7













7.3 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 389 (M++1).
Anal. (C25H24O4) C, H, O.
2-(6′-Methoxynaphthalen-2′-yl)-6,8,8-triethyldesmosdumotin B (12)
1H NMR (300 MHz, CDCl3): δ̣ 13.18 (s, 1H, chelated-OH), 8.24 (d, 1H, J = 1.8 Hz, 1′-H),
7.88 (d, 2H, J = 8.7 Hz, 4′ and 8′-H), 7.76 (dd, 1H, J = 8.7 and 1.8 Hz, 3′-H), 7.27 (dd, 1H, J
= 8.7 and 1.8 Hz, 7′-H), 7.19 (d, 1H, J = 1.8 Hz, 5′-H), 6.99 (s, 1H, 3-H), 3.98 (s, 3H, -
OCH3), 2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.38–2.23 (m, 2H, 8-CH2CH3), 2.14–2.00 (m,
2H, 8-CH2CH3), 1.05 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.70 (t, 6H, J = 7.3 Hz, 8-
CH2CH3×2). Anal. (C26H26O5) C, H, O.
6,8,8-Triethyl-2-(quinolin-3′-yl)desmosdumotin B (13)
1H NMR (300 MHz, CDCl3): δ̣ 12.88 (s, 1H, chelated-OH), 9.29 (d, 1H, J = 2.2 Hz, 2′-H),
8.56 (d, 1H, J = 2.2 Hz, 4′-H), 8.21 (d, 1H, J = 8.5 Hz, 5′-H), 8.00 (d, 1H, J = 7.4 Hz, 8′-H),
7.94–7.86 (m, 1H, 7′-H), 7.72 (dd, 1H, J = 8.5 and 7.4 Hz, 6′-H), 7.09 (s, 1H, 3-H), 2.48 (q,
2H, J = 7.3 Hz, 6-CH2CH3), 2.39–2.25 (m, 2H, 8-CH2CH3), 2.12–1.99 (m, 2H, 8-CH2CH3),
1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z:
390 (M++1). Anal. (C24H23O4N·1/8H2O) C, H, O.
2-(Benzo[d][1′,3′]dioxol-5′-yl)-6,8,8-triethyldesmosdumotin B (14)
1H NMR (300 MHz, CDCl3): δ̣ 13.13 (s, 1H, chelated-OH), 7.37 (dd, 1H, J = 8.2 and 1.8
Hz, 6′-H), 7.20 (d, 1H, J = 1.8 Hz, 4′-H), 6.97 (d, 1H, J = 8.2 Hz, 7′-H), 6.76 (s, 1H, 3-H),
6.12 (s, 2H, 2′-CH2-), 2.45 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.32–2.17 (m, 2H, 8-CH2CH3),
2.03–1.90 (m, 2H, 8-CH2CH3), 1.04 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.67 (t, 6H, J = 7.3 Hz,
8-CH2CH3×2). MS (ESI+) m/z: 383 (M++1). Anal. (C22H22O6·1/4H2O) C, H, O.
2-(2′,3′-Dihydrobenzo[d][1′,4′]dioxin-6′-yl)-6,8,8-triethyldesmosdumotin B (15)
1H NMR (300 MHz, CDCl3): δ̣ 13.17 (s, 1H, chelated-OH), 7.34–7.28 (m, 2H, 5′ and 7′-H),
7.02 (d, 1H, J = 9.2 Hz, 8′-H), 6.77 (s, 1H, 3-H), 4.40–4.30 (m, 4H, -OCH2CH2O-), 2.45 (q,
2H, J = 7.3 Hz, 6-CH2CH3), 2.31–2.16 (m, 2H, 8-CH2CH3), 2.05–1.91 (m, 2H, 8-CH2CH3),
1.04 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.66 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z:
397 (M++1). Anal. (C23H24O6·1/4H2O) C, H, O.
2-(Benzofuran-2′-yl)-6,8,8-triethyldesmosdumotin B (16)
1H NMR (300 MHz, CDCl3): δ̣ 12.98 (1H, chelated-OH), 7.71 (d, 1H, J = 7.7 Hz, 4′-H),
7.60 (d, 1H, J = 7.9 Hz, 7′-H), 7.49 (dd, 1H, J = 7.9 and 7.2 Hz, 6′-H), 7.43 (s, 1H, 3′-H),
7.36 (dd, 1H, J = 7.7 and 7.4 Hz, 5′-H), 7.01 (s, 1H, 3-H), 2.46 (q, 2H, J = 7.4 Hz, 6-
CH2CH3), 2.34–2.18 (m, 2H, 8-CH2CH 3), 2.06–1.92 (m, 2H, 8-CH2CH3), 1.04 (t, 3H, J =
7.4 Hz, 6-CH2CH3), 0.69 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS m/z 351 (M+-1). MS (ESI+)
m/z: 379 (M++1). Anal. (C23H22O5) C, H, O.
2-(Benzo[b]thiophen-2′-yl)-6,8,8-triethyldesmosdumotin B (17)
1H NMR (300 MHz, CDCl3): δ̣ 12.96 (s, 1H, chelated-OH), 7.94–7.88 (m, 2H, 4′ and 7′-H),
7.91 (s, 1H, 3′-H), 7.52–7.46 (m, 2H, 5′ and 6′-H), 6.83 (s, 1H, 3-H), 2.46 (q, 2H, J = 7.4,
Hz, 6-CH2CH3), 2.34–2.21 (m, 2H, 8-CH2CH3), 2.10–1.96 (m, 2H, 8-CH2CH3), 1.05 (t, 3H,
J = 7.4 Hz, 6-CH2CH3), 0.70 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 395
(M++1). Anal. (C23H22O4S) C, H, O.
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1H NMR (400 MHz, CDCl3): δ 13.00 (1H, chelated-OH), 7.91–7.82 (m, 2H, Ar-H), 7.55–
7.45 (m, 2H, Ar-H), 6.82 (s, 1H, 3-H), 2.72 (s, 3H, 3′-CH3), 2.46 (q, 2H, J = 7.4 Hz, 6-
CH2CH3), 2.32–2.20 (m, 2H, 8-CH2CH3), 2.07–1.95 (m, 2H, 8-CH2CH3), 1.05 (t, 3H, J =
7.3 Hz, 6-CH 2CH3), 0.70 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 409 (M++1).
Anal. (C24H24O4S) C, H, O.
2-(Benzofuran-3′-yl)-6,8,8-triethyldesmosdumotin B (19)
1H NMR (400 MHz, CDCl3): δ̣ 13.03 (s, 1H, chelated-OH), 8.23 (s, 1H, 2′-H), 7.90–7.84
(m, 1H, 4′ or 7′-H), 7.68–7.63 (m, 1H, 4′ or 7′-H), 7.53–7.42 (m, 2H, 5′ and 6′-H), 6.89 (s,
1H, 3-H), 2.5–2.42 (m, 2H, 6-CH2CH3), 2.38–2.24 (m, 2H, 8-CH2CH3), 2.06–1.94 (m, 2H,
8-CH2CH3), 1.05 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2).
MS (ESI+) m/z: 379 (M++1). Anal. Not available due to limited quantity.
2-(1′-Methyl-1H-indol-3′-yl)-6,8,8-triethyldesmosdumotin B (20)
1H NMR (300 MHz, CDCl3): δ̣13.61 (1H, chelated-OH), 8.00–7.93 (m, 1H, 4′-H), 7.70 (s,
1H, 2′-H), 7.48–7.34 (m, 3H, 5′, 6′ and 7′-H), 6.79 (s, 1H, 3-H), 3.94 (s, 3H, N-CH3), 2.46
(q, 2H, J = 7.4 Hz, 6- CH2CH3), 2.36–2.21 (m, 2H, 8-CH2CH3), 2.10–1.96 (m, 2H, 8-
CH2CH3), 1.05 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.70 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS
(ESI+) m/z: 392 (M++1). Anal. (C24H25O4N) C, H, O.
2-(Benzo[b]thiophen -3′-yl)-6,8,8-triethyldesmosdumotin B (21)
1H NMR (300 MHz, CDCl3): δ̣ 13.08 (s, 1H, chelated-OH), 8.12–8.06 (m, 1H, 4′-H), 8.07
(s, 1H, 2′-H), 8.02–7.96 (m, 1H, 7′-H), 7.61–7.48 (m, 2H, 5′ and 6′-H), 6.94 (s, 1H, 3-H),
2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.36–2.08 (m, 2H, 8-CH2CH3), 2.07–1.93 (m, 2H, 8-
CH2CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS
(ESI+) m/z: 395 (M++1). Anal. (C23H22O4S·1/8H2O) C, H, O.
2-(2′-Methylbenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmosdumotin B (22)
1H NMR (400 MHz, CDCl3): δ̣ 13.08 (1H, chelated-OH), 7.86–7.82 (m, 1H, 4′-H), 7.72–
7.68 (m, 1H, 7′-H), 7.48–7.38 (m, 2H, 5′ and 6′-H), 6.67 (s, 1H, 3-H), 2.97 (s, 3H, 2′- CH3),
2.48 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.28–2.16 (m, 2H, 8-CH2CH3), 1.98–1.86 (m, 2H, 8-
CH2 CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.70 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS
(ESI+) m/z 409 (M++1). HPLC.
2-(5′-Methylbenzo[B]thiophen-3′-yl)-6,8,8-triethyldesmosdumotin B (23)
1H NMR (400 MHz, CDCl3): δ̣ 13.09 (1H, chelated-OH), 8.03 (s, 1H, 2′-H), 7.89 (br s, 1H,
4′-H), 7.84 (d, 1H, J = 8.4 Hz, 7′-H), 7.34 (dd, 1H, J = 0.98 and 8.4 Hz, 6′-H), 6.93 (s, 1H,
3-H), 2.54 (s, 3H, 5′-CH3), 2.48 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.34–2.22 (m, 2H, 8-
CH2CH3), 2.06–1.95 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.72 (t, 6H,
J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 409 (M++1). Anal. (C24H24O4S) C, H, O.
2-(5′-Bromobenzo[b]thiophen-3′-yl)-6,8,8-triethyldesmosdumotin B (24)
1H NMR (400 MHz, CDCl3): δ̣ 12.97 (1H, chelated-OH), 8.25 (d, 1H, J = 1.9 Hz, 4′-H),
8.07 (s, 1H, 2′-H), 7.84 (d, 1H, J = 8.8 Hz, 7′-H), 7.61 (dd, 1H, J = 1.9 and 8.8 Hz, 6′-H),
6.88 (s, 1H, 3-H), 2.47 (q, 2H, J = 7.3 Hz, 6-CH2CH3), 2.37–2.24 (m, 2H, 8-CH2CH3),
2.05–1.94 (m, 2H, 8-CH2CH3), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.71 (t, 6H, J = 7.3 Hz,
8-CH2CH3×2). MS (ESI+) m/z 473 and 475 (M++1). Anal. (C23H21BrO4S) C, H, O.
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1H NMR (400 MHz, CDCl3): δ̣ 13.19 (1H, chelated-OH), 8.00 (d, 1H, J = 8.8 Hz, Ar-H),
7.63 (d, 1H, J = 5.6 Hz, Ar-H), 7.25 (d, 1H, J = 5.6 Hz, Ar-H), 7.16 (d, 1H, J = 8.8 Hz, Ar-
H), 6.75 (s, 1H, 3-H), 3.92 (s, 3H, 5′-OCH3), 2.47 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.20–
2.10 (m, 2H, 8-CH2CH3), 1.94–1.85 (m, 2H, 8-CH2CH 3), 1.06 (t, 3H, J = 7.4 Hz, 6-
CH2CH3), 0.69 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 425 (M++1). Anal.
(C24H24O5S) C, H, O.
2-(5′-Hydroxybenzo[B]thiophen-4′-yl)-6,8,8-triethyldesmosdumotin B (26)
1H NMR (400 MHz, CDCl3): δ̣ 313.11 (1H, chelated-OH), 7.90 (d, 1H, J = 8.8 Hz, Ar-H),
7.82 (br s, 1H, 5′-OH), 7.63 (d, 1H, J = 5.6 Hz, Ar-H), 7.32 (d, 1H, J = 5.6 Hz, Ar-H), 7.14
(d, 1H, J = 8.8 Hz, Ar-H), 7.12 (s, 1H, 3-H), 2.49 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.25–2.14
(m, 2H, 8-CH2CH3), 2.02–1.91 (m, 2H, 8-CH2CH3), 1.07 (t, 3H, J = 7.4 Hz, 6-CH2CH3),
0.70 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 411 (M++1). Anal. (C23H22O5S) C,
H, O.
2-(Benzo[b]thiophen-7′-yl)-6,8,8-triethyldesmosdumotin B (27)
1H NMR (400 MHz, CDCl3): δ 13.10 (1H, chelated-OH), 8.06 (dd, 1H, J = 7.8 and 0.8 Hz,
4′-H), 7.79 (d, 1H, J = 7.6 Hz 6′-H), 7.62 (d, 1H, J = 5.6 Hz, 2′-H), 7.57 (dd, 1H, J = 7.8 and
7.6 Hz, 5′-H), 7.50 (d, 1H, J = 5.6 Hz, 3′-H), 7.12 (s, 1H, 3-H), 2.48 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.34–2.18 (m, 4H, 8-CH2CH3×2), 1.06 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.70 (t,
6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 395 (M++1). HPLC
2-(Benzo[b]thiophen-5′-yl)-6,8,8-triethyldesmosdumotin B (28)
1H NMR (400 MHz, CDCl3): δ 13.10 (1H, chelated-OH), 8.26 (d, 1H, J = 1.9 Hz, 4′-H),
8.05 (d, 1H, J = 8.5 Hz, 7′-H), 7.72 (dd, 1H, J = 1.9 and 8.5 Hz, 6′-H), 7.62 (d, 1H, J = 5.4
Hz, 2′-H), 7.49 (d, 1H, J = 5.4 Hz, 3′-H), 6.98 (s, 1H, 3-H), 2.46 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.36–2.24 (m, 2H, 8-CH2CH3), 2.10–2.00 (m, 2H, 8-CH2CH3), 1.05 (t, 3H, J =
7.3 Hz, 6-CH2CH3), 0.70 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z 395 (M++1).
HPLC
2-(1′,2′-Dihydroacenaphthylen-5′-yl)-6,8,8-triethyldesmosdumotin B (29)
1H NMR (300 MHz, CDCl3): δ̣ 13.21 (1H, chelated-OH), 7.81 (d, 1H, J = 8.2 Hz, 8′-H),
7.72 (d, 1H, J = 7.5 Hz, 4′-H), 7.61 (dd, 1H, J = 8.2 and 7.5 Hz, 7′-H), 7.46 (d, 1H, J = 7.5
Hz, 3′ or 6′-H), 7.42 (d, 1H, J = 7.5 Hz, 3′ or 6′-H), 6.88 (s, 1H, 3-H), 3.49 (s, 4H, -CH2-×2),
2.48 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.30–2.15 (m, 2H, 8-CH2CH3), 2.04–1.90 (m, 2H, 8-
CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.72 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS
(ESI+) m/z: 415 (M++1). Anal. (C27H26O4) C, H, O.
2-(9′-Ethyl-9′H-carbazol-2′-yl)-6,8,8-triethyldesmosdumotin B (30)
1H NMR (300 MHz, CDCl3): δ̣ 13.31 (1H, chelated-OH), 8.47 (d, 1H, J = 1.8 Hz), 8.29 (d,
1H, J = 1.8 Hz), 7.91 (dd, 1H, J = 1.8 and 8.7 Hz), 7.65 (dd, 1H, J = 1.8 and 8.7 Hz), 7.55
(d, 1H, J = 8.7 Hz), 7.37 (d, 1H, J = 8.7 Hz), 6.97 (s, 1H, 3-H), 4.42 (q, 2H, J = 7.3 Hz, N-
CH2CH3), 2.46 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.40–2.27 (m, 2H, 8-CH2CH3), 2.16–2.03
(m, 2H, 8-CH2CH3), 1.48 (t, 3H, J = 7.3 Hz, N-CH2CH3), 1.06 (t, 3H, J = 7.4 Hz, 6-
CH2CH3), 0.72 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 455 (M++1). Anal. Not
available due to limited quantity.
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1H NMR (300 MHz, CDCl3): δ̣ 13.14 (s, 1H, chelated-OH), 8.18 (dd, 1H, J = 7.8 and 1.4
Hz, 9′-H), 8.03 (dd, 1H, J = 6.9 and 1.4 Hz, 1′-H), 7.94 (dd, 1H, J = 7.8 and 1.4 Hz, 6′-H),
7.73 (s, 1H, 3-H), 7.70 (d, 1H, J = 8.2 Hz, 3′-H), 7.62–7.42 (m, 3H, 2′, 7′ and 8′-H), 2.48 (q,
2H, J = 7.3 Hz, 6-CH2CH3), 2.38–2.24 (m, 2H, 8-CH2CH3), 2.18–2.04 (m, 2H, 8-CH2CH3),
1.07 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.72 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z:
429 (M++1). Anal. (C27H24O5·1/2H2O) C, H, O.
2-(Anthracen-9-yl)- 6,8,8-triethyldesmosdumotin B (32)
1H NMR (300 MHz, CDCl3): δ̣ 13.06 (1H, chelated-OH), 8.70 (s, 1H, 10′-H), 8.17–8.09 (m,
2H, 5′- and 8′-H, or 1′- and 3′-H), 7.83–7.75 (m, 2H, 5′- and 8′-H, or 1′- and 3′-H), 7.61–
7.54 (m, 4H, 2′-, 3′-, 6′- and 7′-H), 6.83 (s, 1H, 3- H), 2.51 (q, 2H, J = 7.4 Hz, 6-CH2CH3),
2.18–2.04 (m, 2H, 8-CH2CH3), 1.84–1.70 (m, 2H, 8-CH2 CH3), 0.88 (t, 3H, J = 7.4 Hz, 6-
CH2CH3), 0.74 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 439 (M++1). Anal.
(C29H26O4·1/2H2O) C, H, O.
2-(Phenanthren-9′-yl)- 6,8,8-triethyldesmosdumotin B (33)
1H NMR (300 MHz, CDCl3): δ̣ 13.06 (1H, chelated-OH), 8.86–8.72 (m, 2H, 4′ and 5′-H),
8.04–7.94 (m, 2H, 1′- and 8′-H), 7.92–7.62 (m, 5H, 2′, 3′, 6′, 7′ and 10′-H), 6.89 (s, 1H, 3-
H), 2.49 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.24–2.11 (m, 2H, 8-CH2CH3), 1.98–1.83 (m, 2H,
8-CH2CH3), 1.07 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.75 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2).
MS (ESI+) m/z: 439 (M++1). Anal. (C29H26O4·1/2H2O) C, H, O.
2-(Biphen-4′-yl)- 6,8,8-triethyldesmosdumotin B (34)
1H NMR (300 MHz, CDCl3): δ̣ 13.08 (1H, chelated-OH), 7.88 (d, 2H, J = 7.8 Hz, 2′- and 6′-
H), 7.78 (d, 2H, J = 7.8 Hz), 7.64 (d, 2H, J = 8.2 Hz), 7.55–7.43 (m, 3H, 8′-, 9′- and 10′-H),
6.95 (s, 1H, 3-H), 2.46 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.36–2.21 (m, 2H, 8-CH2CH3),
2.10–1.96 (m, 2H, 8-CH2CH3), 1.05 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.69 (t, 6H, J = 7.4 Hz,
8-CH2CH3×2). Anal. (C27H26O4) C, H, O.
2-(4′-Methylnaphthalen-1′-yl)-6,8,8-trimethyldesmosdumotin B (35)
1H NMR (400 MHz, CDCl3): δ 13.12 (s, 1H, chelated-OH), 8.16–8.12 (m, 1H, 5′-H), 8.00–
7.96 (m, 1H, naphtyl-H), 7.68–7.57 (m, 3H, naphtyl-H), 7.45 (d, 1H, J = 7.3 Hz, naphtyl-H),
6.79 (s, 1H, 3-H), 2.80 (s, 3H, 4′-CH3), 1.90 (s, 3H, 6-CH3), 1.53 (s, 6H, 8-CH3×2). Anal.
(C23H20O4) C, H, O.
2-(2′,3′-Dihydrobenzo[d][1′,4′]dioxin-6′-yl)-6,8,8-trimethyldesmosdumotin B (36)
1H NMR (400 MHz, CDCl3): δ̣ 13.22 (s, 1H, chelated-OH), 7.34–7.30 (m, 2H, Ar-H), 7.03–
7.00 (m, 1H, Ar-H), 6.77 (s, 1H, 3-H), 4.40–4.30 (m, 4H, -OCH2CH2O-), 1.86 (s, 3H, 6-
CH3), 1.56 (s, 6H, 8-CH3×2). MS (ESI+) m/z: 355 (M++1). Anal. (C20H18O6·1/2H2O) C, H,
O.
2-(Benzo[b]thiophen-3′-yl)-6,8,8-trimethyldesmosdumotin B (37)
1H NMR (400 MHz, CDCl3): δ̣13.08 (s, 1H, chelated-OH), 8.11 (d, 1H, J = 8.1 Hz, 4′ or 7′-
H), 8.07 (s, 1H, 2′-H), 7.98 (d, 1H, J = 8.1 Hz, 4′ or 7′-H), 7.60–7.48 (m, 2H, 5′ and 6′-H),
6.92 (s, 1H, 3-H), 1.90 (s, 3H, 6-CH3), 1.60 (s, 6H, 8-CH3×2). MS (ESI+) m/z: 351 (M+-1).
Anal. (C20H16O4S·1/4H2O) C, H, O.
6,8,8-Triethyl-7-methoxy-2-(naphthalen-1′-yl)-4H-chromene-4,5(8H)-dione (40a)
40a was prepared according to the previously reported procedure.1b
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1H NMR (300 MHz, CDCl3): δ̣ 8.04 (d, 1H, J = 8.2 Hz, Ar-H), 8.00–7.92 (m, 2H, Ar-H),
7.67–7.54 (m, 4H, Ar-H), 6.72 (s, 1H, 3-H), 4.00 (s, 3H, OCH3), 2.60 (q, 2H, J = 7.3 Hz, 6-
CH2CH3), 2.16–2.00 (m, 2H, 8-CH2CH3), 2.24–1.89 (m, 2H, 8-CH2CH3), 1.18 (t, 3H, J =
7.3 Hz, 6-CH2CH3), 0.76 (t, 6H, J = 7.3 Hz, 8-CH2CH3×2). MS (ESI+) m/z: 403 (M++1).
Anal. (C26H26O4) C, H, O.
2-(Naphthalen-1-yl)-4-thioxo-6,8,8-triethyldesmosdumotin B (41)
Lawesson’s reagent (48 mg, 0.12 mmol) was added to a solution of 3 (40 mg, 0.10 mmol) in
toluene (1.5 mL). After refluxing for 6.5 h, the volatile solvent was removed in vacuo. The
residue was purified by SiO2 column chromatography (EtOAc/hexane, gradient) to obtain
41 (20 mg, 50%) and 42 (3 mg, 7%) along with starting material (8 mg, 20%). 1H NMR
(300 MHz, CDCl3): δ̣ 13.50 (1H, chelated-OH), 8.10 (d, 1H, J = 7.9 Hz, 5′-H), 8.02–7.95
(m, 2H, 3′- and 8′-H), 7.73 (dd, 1H, J = 7.2 and 1.1 Hz, 2′-H), 7.66–7.60 (m, 3H, 4′-, 6′- and
7′-H), 7.62 (s, 1H, 3-H), 2.52 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.31–2.07 (m, 2H, 8-
CH2CH3), 2.01–1.86 (m, 2H, 8-CH2CH3), 1.07 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.74 (t, 6H,
J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z 405 (M++1). Anal. (C25H24O3S) C, H, O.
4,7-Dithioxo-2-(naphthalen-1-yl)-6,8,8-triethyldesmosdumotin B (42)
1H NMR (300 MHz, CDCl3): δ̣ 14.30 (1H, chelated-OH), 8.11 (d, 1H, J = 8.2 Hz, 5′-H),
8.03–7.94 (m, 2H, 3′- and 8′-H), 7.76 (dd, 1H, J = 7.4 and 1.3 Hz, 2′-H), 7.67–7.57 (m, 3H,
4′-, 6′- and 7′-H), 7.62 (s, 1H, 3-H), 2.99 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.58–2.42 (m, 2H,
8-CH2CH3), 2.30–2.16 (m, 2H, 8-CH2CH3), 1.10 (t, 3H, J = 7.4 Hz, 6-CH2CH3), 0.64 (t,
6H, J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z 421 (M++1). Anal. (C25H24O2S2·H2O) C, H,
O.
3-Bromo-6,8,8-triethyl-7-methoxy-2-(naphthalen-1′-yl)-4H-chromene-4,5(8H)-dione (43)
PhI(OAc)2 (280 mg, 0.87 mmol) was suspended in anhydrous CH2Cl2 (1.5 mL) under argon
at room temperature. Bu4NBr (281 mg, 0.87 mmol) was added, and the mixture was stirred
for 30 min. 40a (64 mg, 0.16 mmol) in anhydrous CH2Cl2 (1.0 mL) was added, and the
mixture was stirred at room temperature for 4 days. The reaction was quenched with
saturated NH4Cl aq. and extracted with CH2Cl2. The organic layer was dried over Na2SO4,
and the solvent evaporated in vacuo. The residue was purified by SiO2 column
chromatography (EtOAc/hexane, gradient) to obtain 43 (22 mg, 29%).1H NMR (300 MHz,
CDCl3): δ̣ 8.07 (dd, 1H,3J = 2.1 and 7.4 Hz, 5′-H), 8.01–7.96 (m, 1H, Ar- H), 7.68–7.52 (m,
5H, Ar-H), 3.99 (s, 3H, OCH3), 2.61 (q, 2H, J = 7.4 Hz, 6-CH2CH3), 2.10–1.95 (m, 2H, 8-C
H2CH3), 1.90–1.78 (m, 2H, 8-CH2CH3), 1.17 (t, 3H, J = 7.3 Hz, 6-CH2CH3), 0.73 (br s, 6H,
8-CH2CH3×2). MS (ESI+) m/z 481 and 483 (M++1). Anal. (C26H25 BrO4) C, H, O.
3-Bromo-2-(naphthalen-1′-yl)-6,8,8-triethyldesmosdumotin B (44)
To a solution of 43 (18 mg, 0.038 mmol) in anhydrous CH2Cl2 (1.0 ml), BBr3 (0.1 ml, 0.1
mmol, 1.0 M solution in CH2Cl2) was added at −78 °C under N2. The mixture was stirred
overnight at −78 °C to 0 °C. The reaction mixture was quenched with water and extracted
with CH2Cl2. The organic phase was dried over Na2SO4, and concentrated. The residue was
purified by SiO2 column chromatography (EtOAc/hexane, gradient) to obtain 44 (13 mg,
73%).
1H NMR (300 MHz, CDCl3): δ̣ 12.63 (1H, chelated-OH), 8.14–8.08 (m, 1H, 5′-H), 8.03–
7.98 (m, 1H, 8′-H), 7.71–7.52 (m, 5H, 2′-, 3′-, 4′-, 6′-, and 7′-H), 2.49 (q, 2H, J = 7.4 Hz, 6-
CH2CH3), 2.20–2.07 (m, 2H, 8-CH2CH3), 1.87–1.72 (m, 2H, 8-CH2CH3), 1.07 (t, 3H, J =
7.4 Hz, 6-CH2CH3), 0.74 (t, 6H, J = 7.4 Hz, 8-CH2CH3×2). MS (ESI+) m/z 467 and 469
(M++1). Anal. (C22H23BrO4) C, H, O.
Nakagawa-Goto et al. Page 12














Compound 39 (R = Et, Ar = naphthyl,1b 58 mg, 0.14 mmol) was dissolved in HOAc (2.0
mL). 45% HI (1.6 mL) was added to the mixture, which was refluxed for 20 h. The reaction
mixture was cooled to rt, and the solvent was removed in vacuo. Water was added to the
residue. The whole mixture was neutralized to pH 7 with sat. aq. NaHCO3 and extracted
with CH2Cl2. The organic phase was dried over Na2SO4, and concentrated. The residue was
purified by SiO2 column chromatography (EtOAc/hexane, gradient) to obtain 48 (20 mg,
37%). 1H NMR (400 MHz, CDCl3): δ̣ 11.64 (1H, chelated-OH), 8.01–7.92 (m, 3H, naphtyl-
H), 7.64–7.52 (m, 4H, naphthyl- H), 6.37 (dd, 1H, J = 12.3 and 4.1 Hz, 2-H), 3.19 (dd, 1H, J
= 12.3 and 17.3 Hz, 3-Hax), 3.14 (dd, 1H, J = 4.1 and 17.3 Hz, 3-Heq), 2.40 (q, 2H, J = 7.4
Hz, 6-CH2CH3), 2.12–1.98 (m, 2H, 8-CH2CH3), 1.90–1.66 (m, 2H, 8-CH2CH3), 1.00 (t, 3H,
J = 7.4 Hz, 6-CH2CH3), 0.77 (t, 3H, J = 7.4 Hz, 8-CH2CH3), 0.50 (t, 3H, J = 7.4 Hz, 8-
CH2CH3). MS (ESI+) m/z 389 (M+–1). Anal. (C25H26O4) C, H, O
5-Methoxybenzothiophene-3-carboxaldehyde (55)
To a solution of 53 (122 mg, 0.74 mmol) in anhydrous CH2Cl2 (1.5 mL), SnCl4 (1.5 mL, 1.5
mmol, 1.0 M solution in CH2Cl2) was added dropwise at 0 °C under inert gas. Subsquently,
dichloromethyl methyl ether (0.1 mL, 1.11 mmol) was added dropwise at 0 °C. The mixture
was allowed to warm to room temperature and stirred overnight. The mixture was quenched
with sat. NaHCO3 at 0 °C, and stirred for 2 h at room temperature. After extraction with
CH2Cl2, the organic layer was washed with brine, dried over Na2SO4, and concentrated. The
residue was chromatographed on SiO2 with EtOAc-hexane gradient to give 55 (107 mg,
0.56 mmol, 75%). 1H NMR (400 MHz, CDCl3): δ̣ 10.71 (1H, s, CHO), 8.39 (d, 1H, J = 5.6
Hz, 3 -H), 7.97 (d, 1H, J = 9.0 Hz, 7-H), 7.65 (d, 1H, J = 5.6 Hz, 2-H), 7.04 (d, 1H, J = 9.0
Hz, 6-H) 3.96 (s, 3H, OCH3). MS (ESI+) m/z 193 (M++1).
5-Methylbenzothiophene-3-carboxaldehyde (56)
The title compound was prepared in 82% yield following the same procedure as 55 starting
from 54 (119.5 g, 0.81 mmol), SnCl4 (2.4 mL, 2.4 mmol, 1.0 M solution in CH2Cl2) and
dichloromethyl methyl ether (0.11 mL, 1.21 mmol). 1H NMR (400 MHz, CDCl3): δ̣ 10.13
(1H, s,3 CHO), 8.51–8.48 (m, 1H, 4-H), 8.32 (s, 1H, 2-H), 7.86 (d, 1H, J = 8.2 Hz, 7-H),
7.30 (dd, 1H, J = 8.2 and 1.6 Hz, 6-H) 2.5 (s, 3H, CH3). MS (ESI+) m/z 177 (M++1).
Antiproliferative Activity Assay
All stock cultures were grown in T-25 flasks. Freshly trypsinized cell suspensions were
seeded in 96-well microtiter plates at densities of 1500–7500 cells per well, with compounds
added from DMSO stock solutions and then successively diluted into medium. The highest
concentration of DMSO in the cultures (0.5% v/v) was without effect on cell replication
under the culture conditions used. After three days in culture, attached cells were fixed with
cold 50% trichloroacetic acid and then stained with 0.4% sulforhodamine B. The absorbency
at 562 nm was measured using a microplate reader after solubilizing the bound dye. The
mean GI50 is the concentration of agent that reduced cell growth by 50% under the
experimental conditions and is the average from at least three independent and similar
determinations. All values presented in Table 2 are statistically significant and standard
deviations are shown in the support information. For the verapamil reversal experiments,
cells were co-treated with verapamil (1 μg/mL). Control experiments showed this
concentration had no effect on the replication of KB-VIN cells. The following human tumor
cell lines were used in the assay: A549 (lung carcinoma), MCF-7 (breast cancer), HCT-8
(colon adenocarcinoma), PC-3 (prostate cancer), KB (nasopharyngeal carcinoma), and KB-
VIN (vincristine-resistant KB subline). All cell lines were obtained from the Lineberger
Cancer Center (UNC-CH) or from ATCC (Manassas, VA), except KB-VIN, which was a
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generous gift of Professor Y.-C. Cheng, Yale University. Cells were cultured in RPMI-1640
medium supplemented with 25 mM HEPES, 0.25% sodium bicarbonate, 10% fetal bovine
serum, and 100 μg/mL kanamycin.
Tubulin assays
Tubulin assembly was measured by turbidimetry at 350 nm as described previously.15 Assay
mixtures contained 1.0 mg/mL (10 μM) tubulin and varying compound concentrations and
were preincubated 15 min at 30 °C without guanosine 5′-triphosphate (GTP). The samples
were placed on ice, and 0.4 mM GTP was added. Reaction mixtures were transferred to 0 °C
cuvettes, and turbidity development was followed for 20 min at 30 °C following a rapid
temperature jump. Compound concentrations that inhibited increase in turbidity by 50%
relative to a control sample were determined.
Inhibition of the binding of [3H]colchicine to tubulin was measured as described previously.
16 Incubation of 1.0 μM tubulin with 5.0 μM [3H]colchicine and 5.0 μM inhibitor was for 10
min at 37°C, when about 40–60% of maximum colchicine binding occurs in control
samples.
Immunofluorescence staining of tubulin
A549 tumor cells were maintained in 4-well chamber slides (Lab-Tech) for 12 h prior to
treatment with DMSO, 0.1 nM compound 21, 100 nM colchicine, 1.5 nM pacritaxel, or 500
nM doxorubicin for 24 h at 37 °C. Cells were fixed with 4% paraformaldehyde in phospate
buffered saline (PBS), permeabilized with 0.5% Triton X-100 in PBS, and then tubulin was
immunostained with monoclonal antibody to α-tubulin (B5-1-2, Sigma) followed by
fluorescein 5-isothiocyanate (FITC)-conjugated secondary antibody. Nuclei were labeled
with 4′,6-diamidino-2-phenylindole (DAPI).17 Fluorescence labeled tubulin and nuclei were
observed using a Zeiss Axioplan fluorescence microscope and images were captured by a
XL16 Excel cooled digital camera controled by the Dage Exponent Software (Dage-MTI).
Final images were prepared using Adobe Photoshop.
Pharmacophore analysis
Pharmacophore analysis was conducted using Molecular Operating Environment (MOE)
software (version 2009.10, Chemical Computing Group, Inc.). First, low-energy 3D
conformations were calculated for compounds 3, 21 and 26, as well as two known
antitubulin compounds, colchicine and combretastatin-A4 (CA-4). The pharmacophore was
determined by aligning the 3D structures of colchicine and CA-4. This resulting
pharmacophore was later used to search the best-fit 3D confirmations of compounds 3, 21
and 26.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Structures of New Analogues of 1
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Figure 2A: Reversal of MDR-selectivity of 24 by verapamil co-treatment
Figure 2B: Reversal of MDR-selectivity of 27 by verapamil co-treatment
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Figure 3. Effect of compound 21 on microtubule assembly
A549 cells were cultured and treated with agent for 24 hr as indicated. Cells were labeled
immunocytochemically using antibody to α-tubulin (left panels) and DAPI for DNA (right
panels). The mitotic spindles were clearly seen in control (DMSO) and pacritaxel (Tax)
treated cells (arrow heads), while undetectable in the cells treated with 21, colchicine (Col),
or doxorubicine (Dox). The aggregations of tubulin were seen in the prophase cells treated
with 21 or colchicine (arrow). In addition, microtubules were undetectable in the cells
treated with 21 or colchicine, but detectable in cells treated with DMSO, pacritaxel, or
doxorubicine. These observations clearly indicate that 21 inhibits tubulin polymerization in
the human tumor cells. Bar, 10 μm.
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Figure 4. Common pharmacophores of colchicine and CA-4
4A: Five point pharmacophores, H2 (hydrophobic center), R1 (planar group), A1, A2
(hydrogen bond acceptors), and D1 (hydrogen bond donor) for colchicine and CA-4 by
Nguyen.14 4B: The structures of colchicine and CA-4 onto a 3D picture of the five
pharmacophores by MOE. R1 is shown as hydrophobic/aromatic center in this model.
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Figure 5. The alignment of pharmacophore and compounds 3, 21, and 26
Hydrophobic center (H2), planer group (R1), hydrogen bond acceptors (A1 and A2),
hydrogen bond donor (D1)
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Scheme 1. Syntheses of New Analogues of 1
Reagents and conditions: a) ArCHO, base/solvent [piperidine/EtOH for 3-
quinolinecarboxaldehyde, Ba(OH)2·8H2O/MeOH for 4-dimethylamino-1-naphthaldehyde,
and KOH/EtOH for others]; b) I2 (cat.), DMSO, H2SO4 (cat.), 90–95 °C, 1 h; c) BBr3, 0° C
to rt; d) Lawesson’s reagent, toluene, reflux; e) PhI(OAc)2, nBu4NBr, rt; f) 45%HI, HOAc
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Scheme 2. Syntheses of 5-Substituted Benzothiophenecarboxaldehyde
Reagents and conditions: a) 2- chloro-1,1-dimethoxyethane, NaOMe, MeOH, xylene, 110
ºC, b) H3PO4, xylene, 110 ºC, c) Cl2CHOMe, SnCl4, CH2Cl2, rt, 75% for 55, 82% for 56.
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Table 3
Inhibition of Tubulin Assemblya and Colchicine Bindingb
Group Compound IC50 (μM) ± SD Inhibition of colchicine binding (%) ± SD
2 NA -
I
3 2.3 ± 0.08 43 ± 10
6 2.7 ± 0.1 50 ± 0.4
8 2.7 ± 0.3 31 ± 3
11 Not obtainablec 29 ± 0.4
35 2.5 ± 0.2 37 ± 5
II
15 6.5 ± 0.7 33 ± 2
21 2.0 ± 0.1 78 ± 5
22 3.4 ± 0.3 38 ± 4
26 3.4 ± 0.2 52 ± 0.6
36 3.7 ± 0.09 36 ± 4
37 2.4 ± 0.007 69 ± 3
CA-4 1.1 ± 0.1 99 ± 0.7
a
The tubulin assembly assay measured the extent of assembly of 10 μM tubulin after 20 min at 30 °C.
b
Tubulin: 1 sμM, [3H]Colchicine: 5 μM, Inhibitor: 5 μM. Incubation was for 10 min at 37 °C.
c
Partial inhibition observed and was maximal with 4 μM compound. Higher compound concentrations resulted in the same amount of inhibition
observed with 4 μM, suggesting poor solubility of 11 in the reaction mixture.
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